Brain tumors are the most common solid tumor of children and the most common cause of cancer-related deaths. The poor overall outcome of this patient population results from three major issues: 1) The ...
In patients with BRAF-mutated non–small-cell lung cancer (NSCLC), further research is needed to identify more treatment options that address the scope of subsets in this population. Non-V600 mutations ...
The FDA approved encorafenib (Braftovi) plus binimetinib (Mektovi) for BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test, the agency announced on ...
The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial ...
Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions. The Food and Drug Administration (FDA) has granted accelerated approval to ...
Brain metastasis from melanoma is particularly deadly and options are limited due to the difficulty of breaching the brain-blood barrier. Recent research illustrated the potent and prolonged antitumor ...
An investigational novel cream containing a BRAF inhibitor appears to ameliorate the acneiform rash associated with epidermal growth factor receptor (EGFR) inhibitors such as cetuximab (Erbitux) and ...
Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394. Little-known Novellus is licensing the drug, currently in phase 1/2 tests with ...
Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results